Dr. Judge is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Summary
- I am a board-certified specialist in Advanced Heart Failure & Transplant Cardiology, also boarded in Cardiovascular Disease. I direct the Cardiovascular Genetics program at Medical University of South Carolina, and I am also the Fellowship Program Director for Cardiovascular Disease at MUSC in Charleston, SC.
Education & Training
- Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1996 - 2000
- Johns Hopkins UniversityResidency, Internal Medicine, 1993 - 1996
- Perelman School of Medicine at the University of PennsylvaniaClass of 1992
Certifications & Licensure
- SC State Medical License 2018 - 2025
- MD State Medical License 1996 - 2018
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- 1251 citationsLosartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.Jennifer P Habashi, Daniel P. Judge, Tammy M. Holm, Ronald D. Cohn, Bart Loeys
Science. 2006-04-07 - 658 citationsHRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathiesMichael J. Ackerman, Silvia G. Priori, Stephan Willems, Charles I. Berul, Ramon Brugada
Europace. 2011-08-01 - 1002 citationsHRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between ...Michael J. Ackerman, Silvia G. Priori, Stephan Willems, Charles I. Berul, Ramon Brugada
Heart Rhythm. 2011-08-01
Press Mentions
- With Post Hoc Analysis, BridgeBio Touts Case for Acoramidis as FDA Decision Date Draws NearSeptember 30th, 2024
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-Related Hospitalization EventsSeptember 27th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: